Pathology Service Joint Venture

The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>

• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>
• Delivery of a sustainable future pathology workforce<br/>
• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>
• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>
• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>
• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>
• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>
• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>
• A service with capital investment to provide best in class facilities.<br/>
• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>
• An end-to-end comprehensive pathology service<br/>
• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>
• On-site essential services laboratory to support time critical and pathway critical services<br/>
• Histopathology (including immunohistochemistry and receptor analysis)<br/>
• Stem Cell Laboratory<br/>
• Point-of-Care Testing<br/>
• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>
• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>
• Training, Development and Education, Research and Innovation<br/>
• Positive workplace culture<br/>
• IT infrastructure and digital enablement (including Digital Histopathology)<br/>
• Best in class equipment and instrumentation